GlassScriptPhysician profile
Kari Honeycutt
NPI 1942642509
$3,863.88
in general payments reported to CMS, 2019-2025
31 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,704 · 2022: $608 · 2023: $166 · 2024: $209 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.17 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $666.49 | 2021 | |
| Lilly USA, LLC | $433.58 | 2021-2024 | Emgality, Jardiance, Zepbound |
| Astellas Pharma US INC | $427.18 | 2021-2023 | Myrbetriq, Veozah |
| Ucb, INC. | $409.53 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $385.40 | 2021-2022 | |
| Amgen INC. | $227.56 | 2021-2022 | |
| Abbvie INC. | $186.53 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $166.48 | 2021-2025 | |
| Mylan Specialty L.P. | $157.01 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $80.76 | 2021-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $77.66 | 2021-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.85 | 2021 | |
| Jazz Pharmaceuticals INC. | $72.65 | 2021 | |
| Glaxosmithkline, LLC. | $58.08 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Adamas Pharmaceuticals, INC. | $52.57 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.32 | 2021 | |
| Pfizer INC. | $50.80 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $43.71 | 2024-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $30.03 | 2022 | |
| Neurocrine Biosciences, INC. | $25.89 | 2024 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $25.01 | 2021 | |
| Sk Life Science, INC. | $19.02 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.00 | 2025 | |
| Lundbeck LLC | $17.44 | 2025 | Rexulti |
| Medtronic, INC. | $17.31 | 2022 | |
| Neurelis, INC. | $17.18 | 2024 | Valtoco |
| Sanofi-Aventis U.S. LLC | $16.61 | 2022 | |
| Merck Sharp & Dohme LLC | $15.53 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.27 | 2022 | |
| Exact Sciences Corporation | $13.88 | 2025 | The Cologuard Plus Collection Kit |
| Radius Health, INC. | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Honeycutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.